Request Demo
Last update 14 Aug 2025
DeNovaMed, Inc.
Last update 14 Aug 2025
Overview
Basic Info
Introduction DeNovaMed, Inc. is a company that specializes in creating antibiotics to combat infections caused by drug-resistant bacteria, also known as superbugs. Their primary focus is on treating Gram-positive infections, including those caused by methicillin-resistant Staph and vancomycin-resistant Enterococcus. These infections pose a significant risk to patients in healthcare settings, such as hospitals and community health facilities, as they can lead to skin, wound, and systemic infections. Additionally, the company has an ongoing research program for Gram-negative adjuvants, which have the potential to enhance the effectiveness of older antibacterial treatments. DeNovaMed, Inc. was established in 2006 by Donald F. Weaver, Christopher R. McMaster, and David Byers, and is headquartered in Halifax, Canada. |
Tags
Infectious Diseases
Nervous System Diseases
Cardiovascular Diseases
Small molecule drug
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
No Data
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
100 Clinical Results associated with DeNovaMed, Inc.
Login to view more data
Login to view more data
A new class of antibiotics that inhibit bacterial lipid metabolism
Author: Barden, Christopher J. ; Byers, David M. ; Paul, Nawal K. ; Lu, Erhu ; Weaver, Donald F. ; Henneberry, Annette L. ; McMaster, Christopher R. ; Wu, Fan
The research presented here is a novel family of anti-infective compounds that disarm pathogens by blocking the synthesis of endotoxin.Min. inhibitory concentrations for this class are within the potency range of vancomycin for isolates of methicillin-resistant S. aureus (MRSA) and a wide variety of other Gram pos. pathogens.Lead compounds in this class have been shown to be nontoxic at 300 mg/kg in an acute toxicity study and have shown effectiveness in a mouse model of topical MRSA infection.The compound class also contains members with the ability to potentiate older drugs that are otherwise unusable in a clin. setting.The broad-spectrum potential of these novel anti-infective compounds is outlined.
100 Deals associated with DeNovaMed, Inc.
Login to view more data
100 Translational Medicine associated with DeNovaMed, Inc.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 23 Aug 2026
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
Preclinical
Other
3
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free